Stockscreener 앱 받기
6.02
4.14%
-0.26
전일 마감가:
$6.28
열려 있는:
$6.27
하루 거래량:
159.20K
Relative Volume:
0.72
시가총액:
$352.66M
수익:
$34.16M
순이익/손실:
$-98.43M
주가수익비율:
-2.5726
EPS:
-2.34
순현금흐름:
$-119.33M
1주 성능:
+16.67%
1개월 성능:
+34.37%
6개월 성능:
+2.38%
1년 성능:
+43.33%
1일 변동 폭
$6.00
$6.4295
1주일 범위
$5.40
$6.95
52주 변동 폭
$2.9448
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
6.02 | 367.89M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | BTIG Research | Buy |
| 2025-11-07 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 재개 | B. Riley Securities | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics - Quantisnow
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26 - Investing.com Canada
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium - GlobeNewswire
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target - Investing.com Canada
Foghorn Therapeutics Announces $50 Million Equity Financing - TipRanks
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Insider Trends: Will Foghorn Therapeutics Inc stock benefit from green energy trendsJuly 2025 Review & Real-Time Stock Movement Alerts - Bộ Nội Vụ
What momentum indicators show for Foghorn Therapeutics Inc. stockJuly 2025 Catalysts & Safe Entry Trade Signal Reports - Улправда
Foghorn Therapeutics Inc. Secures $50 Million in Equity Financing to Advance Oncology Pipeline and Strengthen Balance Sheet - Quiver Quantitative
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 - Yahoo Finance
Biotech raises $50M to push new lung and breast cancer drugs forward - Stock Titan
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic ... - Bluefield Daily Telegraph
Will Foghorn Therapeutics Inc. stock benefit from green energy trends - Улправда
Can Foghorn Therapeutics Inc. stock sustain free cash flow growthWeekly Investment Report & High Accuracy Trade Signal Alerts - Улправда
Can Foghorn Therapeutics Inc. stock reach $100 price targetEarnings Beat Highlights & Swing Trade Smarter With Data Insights - bollywoodhelpline.com
Why Foghorn Therapeutics Inc. stock is recommended by analystsRisk-Reward Ratio Analysis & Small Budget Big Profits - Улправда
Will Foghorn Therapeutics Inc. stock continue upward momentumBull Market Opportunities & Outstanding Wealth Building - ulpravda.ru
Is Foghorn Therapeutics Inc. stock a bargain at current levels2026 world cup usa national team group stage top scorers possession football odds analysis expert opinion - Улправда
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
Can Foghorn Therapeutics Stock Hold Up When Markets Turn? - Trefis
Is Foghorn Therapeutics Inc. stock resilient to inflation2025 Support & Resistance & Real-Time Chart Breakout Alerts - Улправда
BTIG Research Begins Coverage on Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Buy" - MarketBeat
Is Foghorn Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Decliners & AI Forecast Swing Trade Picks - bolumsonucanavari.com
How Foghorn Therapeutics Inc. stock performs after earningsJuly 2025 Drop Watch & Reliable Breakout Stock Forecasts - Улправда
Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from Analysts at BTIG Research - MarketBeat
Will Foghorn Therapeutics Inc. stock deliver better than expected guidanceWeekly Stock Recap & Proven Capital Preservation Tips - Улправда
Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation - Sahm
BTIG Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - Yahoo Finance
BTIG Research Initiates Coverage on Foghorn Therapeutics With Buy Rating, $11 Price Target - MarketScreener
BTIG Initiates Coverage on FHTX with a Buy Rating and $11.00 Pri - GuruFocus
Support Test: What momentum indicators show for Foghorn Therapeutics Inc. stockPortfolio Return Report & Low Risk Investment Opportunities - Улправда
BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) vs. Arcadia Biosciences (NASDAQ:RKDA) Head to Head Analysis - Defense World
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Analyst Confidence Rises for Foghorn Therapeutics Following Leadership and Pipeline Updates - AD HOC NEWS
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen - Defense World
Is Foghorn Therapeutics Inc. stock attractive for hedge fundsJobs Report & AI Driven Stock Reports - Newser
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher - The Globe and Mail
Stifel Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
Stifel Initiates Coverage on FHTX with a 'Buy' Rating | FHTX Sto - GuruFocus
Foghorn Therapeutics Inc appoints Jeff Sacher as interim CFO - marketscreener.com
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer By Investing.com - Investing.com Nigeria
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer - Investing.com
Why Foghorn Therapeutics Inc. stock remains on buy listsJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):